新辅助化疗治疗晚期上皮性卵巢癌的临床疗效及预后分析

Clinical efficacy and prognosis of neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian cancer

目的探讨新辅助化疗治疗晚期上皮性卵巢癌的临床疗效及对患者预后的影响。方法将102例晚期上皮性卵巢癌患者按治疗方案的不同分为研究组(52例,接受新辅助化疗联合肿瘤细胞减灭术)和对照组(50例,接受肿瘤细胞减灭术)。比较两组患者的临床疗效、生存情况及不良反应发生情况。结果研究组患者疾病控制率高于对照组,差异有统计学意义(P﹤0.05)。研究组患者2年生存率高于对照组,差异有统计学意义(P﹤0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论新辅助化疗治疗晚期上皮性卵巢癌可显著提高疗效,控制疾病进展,同时还能提高患者生存率,具有一定安全性。

Objective To investigate the clinical efficacy and prognosis of neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian cancer.Method A total of 102 patients with advanced epithelial ovarian cancer were divided into study group(52 patients,receiving neoadjuvant chemotherapy combined with cytoreductive surgery)and control group(50 patients,receiving cytoreductive surgery)according to different treatment options.The clinical efficacy,survival,and incidence of adverse reactions of the two groups were compared.Result The disease control rate in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).The 2-year survival rate in the study group was higher than that in the control group,and the difference was statistically significant(P<0.05).The total incidence of adverse events between the two groups was not statistically significant(P>0.05).Conclusion Neoadjuvant chemotherapy for advanced epithelial ovarian cancer could significantly improve efficacy and control disease progression.At the same time,it could also improve the survival rate of patients and have a certain degree of safety.